Use of ustekinumab after other biological therapies in moderate-severe psoriasis: Real long-term data
Objective: Ustekinumab is used in moderate-severe plaque psoriasis with inadequate response to anti- tumour necrosis factor α drugs. Recent studies support the need to assess real long-term data. The aim of this study was to evaluate the real long-term effectiveness and safety of ustekinuma...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Grupo Aula Médica
2020-09-01
|
Series: | Farmacia Hospitalaria |
Subjects: | |
Online Access: | http://www.aulamedica.es/fh/pdf/11420.pdf |